has advised Stemline Therapeutics. Inc. on its initial public offering. Trumpeted by the BioWorld
headline "Stemline Therapeutics Is First Biotech IPO of 2013", the offering was well received by investors, soaring 15% on its first day of trading on the Nasdaq. The team included Ben Ferrucci on executive compensation. Ralph Loren provided counsel on intellectual property issues. Edwards Wildman has represented Stemline as general outside counsel since 2007, including with respect to several private financing and licensing matters.